Analyst Price Target is $90.88
▲ +9.93% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $90.88, with a high forecast of $130.00 and a low forecast of $55.00. The average price target represents a 9.93% upside from the last price of $82.67.
Current Consensus is
The current consensus among 8 contributing investment analysts is to buy stock in Enanta Pharmaceuticals. This rating changed within the last month from a Hold consensus rating.
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.